Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tipranavir: a ritonavir-boosted protease inhibitor.

Drugs - 1 Jan 2005

Croom Katherine F, Keam Susan J

Abstract excerpt

Tipranavir is a non-peptidic HIV-1 protease inhibitor. It binds strongly and selectively, has a favourable resistance profile, and is administered orally twice daily with a subtherapeutic dosage of ritonavir in a 'boosted' regimen (TPV/r) in order to increase its bioavailability. Analysis of clinical isolates from treatment-experienced patients identified the following tipranavir resistance-associated HIV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Drug Administration Schedule
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Pyridines

Share to Pyrones

Share to Ritonavir

Source

Identifiers

PMID: 16060700
DOI: 10.2165/00003495-200565120-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tipranavir: a ritonavir-boosted protease inhibitor.PMID 16060700Read ↗

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Tipranavir.Semantic proximity Read ↗

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.Semantic proximity Read ↗

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.Semantic proximity Read ↗

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Semantic proximity Read ↗

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Semantic proximity Read ↗

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.Semantic proximity Read ↗

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.Semantic proximity Read ↗

Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.Semantic proximity Read ↗

[Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].Semantic proximity Read ↗

Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.Semantic proximity Read ↗

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.